Novel D-ring analogues of podophyllotoxin as potent anti-cancer agents

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 11, 1998, Pages 1391-1396

  Subrahmanyam, Duvvuri ^a   Renuka, B ^a   Rao, C V Laxmana ^a   Sagar, P Sangeeta ^a   Deevi, Dhanvanthri S ^a   Babu, J Moses ^a   Vyas, K ^a  

^a DR REDDY S RESEARCH FOUNDATION   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ETOPOSIDE; PODOPHYLLOTOXIN DERIVATIVE; TENIPOSIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CYTOTOXICITY; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; PODOPHYLLOTOXIN; TUMOR CELLS, CULTURED;

EID: 0032474530     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00232-7     Document Type: Article

References (23)

1. 1) Bohlin, L.; Rosen, B., Drug Discovery Today, 1996, 1, 343-351.
2. 2) (a) Alton, P.A.; Harris, A.L., Annulation Br. J. Haematol., 1993, 85, 241-245;
3. (b) Liu, L.F.; Wang. J.C., Biochemistry of DNA Topoisomerases and their Poisons. In DNA Topoisomerases in Cancer ; Potonesil, M.; Kohn, K.W., Ed.: Oxford University Press ; New York, 1991, pp 13-22.
4. 3) (a) Van Maarien, J.M.S.; Retal, J.; De Vries, J.; Pincedo, H.M.; A review, J. Natl.Cancer.Inst., 1988, 80, 1526-1533;
5. (b) Hainsworth, J.D.; Williams. S. D.; Einhorn, L.H.; Birch. R.; Greco, F.A.; J.Clin.Oncol., 1985, 3, 666-671 ;
6. (c) Shah, J.C.; Chen, J.R.; Chow, D.; Pharm. Res., 1989, 6, 408-412;
7. 4) (a) For a review on synthetic analogues : Ward, R.S.; Synthesis, 1992, 719-730;
8. (b) Forsey, S.P.; Rajapaksa, D.; Taylor, N.J.; Rodrigo. R., J.Org.Chem., 1989, 54, 4280-4290;
9. (c) Wang, Z-Q.; Hu, H.; Chen, H.X.; Cheng, Y-C.; Lee, K-H., J.Med.Chem., 1992, 35, 871-877;
10. (d) Terada, T.; Fujimoto, K.; Nomura, M.; Yamashita, J.; Wierzba, K.; Yamazaki, R.; Shibata, J.; Sugimoto, Y.; Yamada, Y.; Kobunai, T.; Takeda, S.; Minami, Y.; Yoshida, K.; Yamaguchi, H., J.Med.Chem., 1993, 36, 1689-1699 ;
11. (e) Cho, S. J.; Kashiwada, Y.; Bastow, K.F.; Cheng, Y-C.; Lee, K-H., J.MedChem., 1996, 39, 1396-1402;
12. 5) (a) San Feliciano, A.; Gordaliza, M.; Miguel del Corral, J.M.; Castro, M.A.; Garcia-Gravalos, M.D.; Ruiz-Lazaro, P., Planta Med., 1993, 59, 246-249;
13. (b) Gordaliza, M.; Castro, M.A.; Garcia-Gravalos, M.D.; Ruiz-Lazaro, P.; Miguel del Corral, J.M.; San Feliciano, A., Arch.Pharm. (Weinheim) 1994,327, 175-179.
14. 6) Stahelin, H.; Cerletti, A., Schweiz. Med Wschr., 1964, 94, 1490-1502.
15. 7) Falkson, G.; Sandison, A.G.; Vonzyl, J., S.Afr. J.Radio., 1964, 2, 1-7; Vaitkevicius, V.K.; Reed, M.I.; Cancer Chemother.Rep., 1966, 50,565-571.
16. 7) Falkson, G.; Sandison, A.G.; Vonzyl, J., S.Afr. J.Radio., 1964, 2, 1-7; Vaitkevicius, V.K.; Reed, M.I.; Cancer Chemother.Rep., 1966, 50,565-571.
17. 8) (a) Chen, Y.; Wang, Y.; Tian, X.; Li, J., Current Science, 1990, 59, 517-518;
18. (b) Gordaliza, M.; Faircloth, G.T.; Castro, M.A.; Jose, M.; Miguel del Corral, J.M.; Lopez-Vazquez, M.L.; San Feliciano, A., J.Med.Chem., 1996, 39, 2865-2868;
19. (c) Wang, J.; Tian, X.; Tsumura, H.; Shimura, K.; Ito, H.; Anti-Cancer Drug Design, 1993, 8, 193-202.
20. 2.
21. 2O exchangeble, 1H), 5.20(d, J=10Hz,1H), 4.80(dd, J=10Hz, 6Hz, 1H), 4.48(d, J=6Hz, 1H), 4.15(t, J=12Hz, 1H), 3.80(s,6H), 3.57(s, 3H), 3.07(dd, J=12Hz, 6Hz, 1H), 2.95-2.70(m,1H) .
22. 11) (a)Boyd, M.R.; Paull, K.D.; Drug Dev. Res., 1995, 34, 91-109;
23. (b) Paull, K.D.; Shoemaker, R.H.; Hodes, L.; Monks, A.; Scudiero, D.A.; Rubinstein, L.; Plowman, J.; Boyd, M.R., J.Natl.Cancer Inst. 1989, 81, 1088-1092.